|
1
|
Adjuvant trastuzumab in HER2-positive breast cancer.
|
N Engl J Med
|
2011
|
12.52
|
|
2
|
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
|
J Clin Oncol
|
2012
|
8.74
|
|
3
|
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
|
Lancet
|
2010
|
8.14
|
|
4
|
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
|
Lancet
|
2010
|
5.79
|
|
5
|
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
|
Lancet Oncol
|
2011
|
5.63
|
|
6
|
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
|
J Clin Oncol
|
2006
|
3.52
|
|
7
|
Response-guided neoadjuvant chemotherapy for breast cancer.
|
J Clin Oncol
|
2013
|
3.29
|
|
8
|
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
|
J Natl Cancer Inst
|
2008
|
3.21
|
|
9
|
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
|
J Clin Oncol
|
2005
|
2.70
|
|
10
|
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
|
J Clin Oncol
|
2010
|
2.48
|
|
11
|
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
|
J Clin Oncol
|
2012
|
2.45
|
|
12
|
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
|
J Natl Cancer Inst
|
2004
|
2.06
|
|
13
|
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.
|
Clin Cancer Res
|
2014
|
1.86
|
|
14
|
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
|
Ann Surg Oncol
|
2011
|
1.83
|
|
15
|
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.
|
J Clin Oncol
|
2003
|
1.83
|
|
16
|
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
|
Breast Cancer Res Treat
|
2010
|
1.60
|
|
17
|
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
|
Lancet Oncol
|
2011
|
1.59
|
|
18
|
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
|
Breast Cancer Res Treat
|
2005
|
1.53
|
|
19
|
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
|
J Clin Oncol
|
2010
|
1.51
|
|
20
|
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
|
J Clin Oncol
|
2009
|
1.33
|
|
21
|
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.
|
Clin Cancer Res
|
2012
|
1.27
|
|
22
|
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.
|
Clin Cancer Res
|
2013
|
1.15
|
|
23
|
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
|
Cancer
|
2002
|
1.11
|
|
24
|
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
|
J Clin Oncol
|
2005
|
1.09
|
|
25
|
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
|
Clin Cancer Res
|
2005
|
1.07
|
|
26
|
Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator.
|
BMC Cancer
|
2013
|
1.03
|
|
27
|
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
|
Eur J Cancer
|
2006
|
0.95
|
|
28
|
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).
|
Breast Care (Basel)
|
2009
|
0.92
|
|
29
|
BRCA2 mutations and triple-negative breast cancer.
|
PLoS One
|
2012
|
0.89
|
|
30
|
Reducing the global breast cancer burden: the importance of patterns of care research.
|
Clin Breast Cancer
|
2005
|
0.89
|
|
31
|
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
|
Clin Cancer Res
|
2003
|
0.87
|
|
32
|
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.
|
Eur J Cancer
|
2007
|
0.86
|
|
33
|
Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades.
|
Arch Gynecol Obstet
|
2013
|
0.84
|
|
34
|
PTK7 expression in triple-negative breast cancer.
|
Anticancer Res
|
2013
|
0.81
|
|
35
|
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
|
Oncologist
|
2013
|
0.77
|
|
36
|
Technical improvement of pO(2) measurements in breast cancer: investigation of the feasibility in patients and in vitro validation of the method.
|
Strahlenther Onkol
|
2007
|
0.76
|
|
37
|
Increased prevalence of colorectal adenomas in women with breast cancer.
|
Digestion
|
2005
|
0.76
|
|
38
|
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
|
MMW Fortschr Med
|
2003
|
0.75
|